Cargando…
Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment
BACKGROUND: Treatment of the coronavirus disease (COVID-19) is still challenging due to the lack of evidence-based treatment protocols and continuously changing epidemiological situations and vaccinations. Remdesivir (RDV) is among the few antiviral medications with confirmed efficacy for specific p...
Autores principales: | Polivka, Lorinc, Gajdacsi, Jozsef, Fazekas, Levente, Sebok, Szilvia, Barczi, Eniko, Hidvegi, Edit, Sutto, Zoltan, Dinya, Elek, Maurovich-Horvat, Pal, Szabo, Attila J, Merkely, Bela, Müller, Veronika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society of Global Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428504/ https://www.ncbi.nlm.nih.gov/pubmed/36040909 http://dx.doi.org/10.7189/jogh.12.05031 |
Ejemplares similares
-
Remdesivir in Solid Organ Recipients for COVID-19 Pneumonia
por: Fesu, Dorottya, et al.
Publicado: (2022) -
Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease
por: Fesu, Dorottya, et al.
Publicado: (2023) -
Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox
por: Nagy, Alexandra, et al.
Publicado: (2022) -
Risk of COVID-19 hospitalizations among school-aged children in Scotland: A national incident cohort study
por: Shi, Ting, et al.
Publicado: (2022) -
Survival of Myocardial Infarction Patients with Diabetes Mellitus at the Invasive Era (Results from the Városmajor Myocardial Infarction Registry)
por: Skoda, Réka, et al.
Publicado: (2023)